Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3-<36 months.
19 Apr, 2010
Authors: Paediatric European Network for Treatment of AIDS (PENTA) Published in: Antivir Ther. 2010;15(3):297-305. Background Once-daily dosing of abacavir and lamivudine has been approved for adults, but paediatric data are…
Read More
PENTA 15: plasma pharmacokinetic study of once versus twice daily abacavir and lamivudine as part of combination antiretroviral therapy in HIV-1 infected children aged 3 to <36 months.
19 Nov, 2009
Authors: Jacqz-Aigrain, Farrelly L, Compagnucci A, Harrison L, Zhao W, Hamadache D, Welch S, Wintergerst U, Firtion G, Burger D Published in: CROI 2009. February 8-11, 2009. Palais des Congres…
Read More
PENTA 15: Once-daily abacavir and lamivudine as part of combination antiretroviral therapy to 48 weeks in HIV-1 infected children aged 3 to 36 months.
19 Jul, 2009
Authors: Zhao W, Farrelly L, Compagnucci A, Harrison L, Jacqz-Aigrain E, Hamadache D, Welch S, Wintergerst U, Burger D on behalf of the PENTA Trial Steering Committee . Published in:…
Read More